Meeting
2022 ASCO Annual Meeting
A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary cancer.
Authors
Jie Shen
The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Jie Shen , Weiwei Kong , Sihui Zhu , Baorui Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
ChiCTR2000037847
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4077)
DOI
10.1200/JCO.2022.40.16_suppl.4077
Abstract #
4077
Poster Bd #
65
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Updated results from the phase II study: Efficacy and safety of anlotinib plus sintilimab as second-line treatment for patients with advanced biliary tract cancers.
First Author: Shuiling Jin
Poster
2021 Gastrointestinal Cancers Symposium
Phase II study of anlotinib plus sintlimab as second-line treatment for patients with advanced biliary tract cancers.
First Author: Hong Zong
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial.
First Author: Shui-Ling Jin
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II study of paclitaxel and carboplatin plus PD-1 inhibitors combined with anlotinib as first-line treatment for advanced esophageal cancer.
First Author: Mingfang Xu